Revelation Biosciences (NASDAQ:REVBW – Get Free Report) is anticipated to issue its results before the market opens on Thursday, November 5th. Analysts expect Revelation Biosciences to announce earnings of ($6.16) per share for the quarter.
Revelation Biosciences Stock Up 1.8%
NASDAQ REVBW opened at $0.01 on Thursday. The business has a 50-day moving average price of $0.01 and a 200-day moving average price of $0.01. Revelation Biosciences has a twelve month low of $0.00 and a twelve month high of $0.04.
About Revelation Biosciences
Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that harness the body’s innate immune system to prevent and treat disease. The company’s programs are based primarily on Gemini, its proprietary formulation of an innate immune modulator designed for administration through the nose.
Revelation’s product candidates are being investigated for potential use in respiratory and other infectious diseases, with research aimed at stimulating an early immune response in the nasal passages and airways.
Further Reading
- Five stocks we like better than Revelation Biosciences
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
